Table 2. Cardiotoxicity risk and cardiovascular outcomes in 499 patients with solid or hematological neoplasms undergoing chemotherapy and/or chest radiotherapy.
| Cardiovascular outcome | Cardiotoxicity risk | |||||
| Total patients n (%) | Very high risk n (%) 220/499 (44.1) | High risk n (%) 61/499 (12.2) | Intermediate risk n (%) 70/499 (14) | Low risk n (%) 113/499 (22.6) | Very low risk n (%) 35/499 (7) | |
| Chemotherapy associated left ventricular systolic dysfunction | 22 (4.4) | 11/22 (50) | 5/22 (22.7) | 2/22 (9) | 2/22 (9) | 2/22 (9) |
| Death from any cause | 80 (16) | 44/80 (55) | 10/80 (12.5) | 7/80 (8.7) | 15/80 (18.7) | 4/80 (5) |
| Tachyarrhythmia | 14 (2.8) | 6/14 (42.8) | 3/14 (21.4) | 2/14 (14.2) | 3/14 (21.4) | 0/14 (0) |
| Cardiovascular hospital admission | 7 (1.4) | 5/7 (71.4) | 1/7 (14.2) | 0/7 (0) | 1/7 (14.2) | 0/7 (0) |
| Bradyarrhythmia | 1 (0.2) | 1/1 (100) | 0/1 (0) | 0/1 (0) | 0/1 (0) | 0/1 (0) |
| Acute myocardial infarction | 4 (0.8) | 2/4 (50) | 0/4 (0) | 0/4 (0) | 1/4 (25) | 1/4 (25) |
| Stroke | 1 (0.2) | 0/1 (0) | 0/1 (0) | 0/1 (0) | 0/1 (0) | 1/1 (100) |
| Global longitudinal strain decrease >15% | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |